Total Payments
$56,958
2024 Payments
$9,141
Companies
35
Transactions
149
Medicare Patients
15,166
Medicare Billing
$3.3M
Payment Breakdown by Category
Consulting$43,063 (75.6%)
Other$7,824 (13.7%)
Food & Beverage$3,533 (6.2%)
Research$1,624 (2.9%)
Travel$684.42 (1.2%)
Education$230.28 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $43,063 | 19 | 75.6% |
| Honoraria | $3,775 | 3 | 6.6% |
| Food and Beverage | $3,533 | 87 | 6.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500 | 1 | 4.4% |
| Unspecified | $1,624 | 1 | 2.9% |
| Long term medical supply or device loan | $1,549 | 18 | 2.7% |
| Travel and Lodging | $684.42 | 6 | 1.2% |
| Education | $230.28 | 14 | 0.4% |
Payments by Type
General
$55,334
148 transactions
Research
$1,624
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,903 | 28 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $8,484 | 12 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $8,026 | 11 | $0 (2024) |
| Janssen Biotech, Inc. | $4,190 | 5 | $0 (2024) |
| BeiGene USA, Inc. | $3,900 | 2 | $0 (2024) |
| Seagen Inc. | $3,434 | 3 | $0 (2022) |
| Lilly USA, LLC | $3,395 | 20 | $0 (2024) |
| Gilead Sciences, Inc. | $2,759 | 5 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $2,586 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,444 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,141 | 33 | BeiGene USA, Inc. ($3,900) |
| 2023 | $3,399 | 13 | Gilead Sciences, Inc. ($2,747) |
| 2022 | $5,960 | 13 | CTI BioPharma Corp. ($1,725) |
| 2021 | $2,788 | 4 | G1 Therapeutics, Inc. ($1,500) |
| 2020 | $8,073 | 22 | Seagen Inc. ($3,405) |
| 2019 | $16,913 | 24 | Novartis Pharmaceuticals Corporation ($7,257) |
| 2018 | $4,654 | 24 | Takeda Pharmaceuticals U.S.A., Inc. ($2,422) |
| 2017 | $6,030 | 16 | Bayer HealthCare Pharmaceuticals Inc. ($3,198) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $18.33 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/20/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: Neurology | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 11/11/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $27.33 | General |
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $13.68 | General |
| Category: Hematology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 09/26/2024 | GENZYME CORPORATION | CABLIVI (Biological), ENJAYMO | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Hematology | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $6.14 | General |
| Category: Immunology | ||||||
| 09/10/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $33.34 | General |
| Category: Hematology | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.86 | General |
| Category: Hematology | ||||||
| 06/28/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $1,470.00 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 05/31/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $83.33 | General |
| Category: Oncology | ||||||
| 04/19/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $9.04 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $1,624 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 56 | 3,277 | 43,302 | $3.6M | $854,004 |
| 2022 | 54 | 3,215 | 20,431 | $2.5M | $583,470 |
| 2021 | 69 | 4,158 | 51,423 | $4.0M | $976,089 |
| 2020 | 63 | 4,516 | 39,104 | $4.0M | $919,481 |
Total Patients
15,166
Total Services
154,260
Medicare Billing
$3.3M
Procedure Codes
242
All Medicare Procedures & Services
242 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 11,200 | $1.5M | $483,630 | 31.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 55 | 75 | $360,150 | $86,385 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 290 | 537 | $197,616 | $49,979 | 25.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,100 | $137,760 | $38,265 | 27.8% |
| 78816 | Nuclear medicine study whole body with ct scan | Office | 2023 | 19 | 25 | $123,225 | $29,073 | 23.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 78 | 231 | $82,467 | $21,410 | 26.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 100 | 172 | $121,604 | $17,333 | 14.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 79 | 111 | $55,056 | $15,032 | 27.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 82 | 90 | $62,460 | $12,189 | 19.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 71 | 97 | $63,729 | $8,732 | 13.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 358 | 810 | $51,840 | $8,370 | 16.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 3,270 | $65,400 | $7,741 | 11.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 46 | 46 | $32,614 | $7,616 | 23.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 357 | 871 | $17,420 | $7,308 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 356 | 829 | $29,844 | $6,293 | 21.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 44 | $161,700 | $5,929 | 3.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 24 | 99 | $20,889 | $5,665 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 77 | $19,250 | $4,619 | 24.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 67 | $16,549 | $4,138 | 25.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 55 | 73 | $22,849 | $3,603 | 15.8% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 11 | 6,900 | $89,700 | $2,354 | 2.6% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 82 | 112 | $14,336 | $2,284 | 15.9% |
| 85055 | Reticulated (young) platelet measurement | Office | 2023 | 30 | 62 | $8,866 | $2,127 | 24.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 25 | 41 | $14,104 | $1,974 | 14.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 78 | 121 | $7,260 | $1,617 | 22.3% |
About Dr. Sanjay Oommen, MD
Dr. Sanjay Oommen, MD is a Internal Medicine healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457453599.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sanjay Oommen, MD has received a total of $56,958 in payments from pharmaceutical and medical device companies, with $9,141 received in 2024. These payments were reported across 149 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($43,063).
As a Medicare-enrolled provider, Oommen has provided services to 15,166 Medicare beneficiaries, totaling 154,260 services with total Medicare billing of $3.3M. Data is available for 4 years (2020–2023), covering 242 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Fort Worth, TX
- Active Since 09/01/2006
- Last Updated 01/24/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1457453599
Products in Payments
- TASIGNA (Drug) $7,235
- Xofigo (Drug) $5,322
- Stivarga (Drug) $3,162
- DARZALEX (Biological) $2,732
- Tavalisse (Drug) $2,586
- TAGRISSO (Drug) $2,513
- ICLUSIG (Drug) $2,422
- BRUKINSA (Drug) $2,275
- Vonjo (Drug) $1,725
- ENHERTU (Biological) $1,665
- TEVIMBRA (Drug) $1,625
- IMBRUVICA (Drug) $1,515
- COSELA (Drug) $1,500
- CARVYKTI (Drug) $1,470
- CALQUENCE (Drug) $1,388
- KISQALI (Drug) $1,306
- IMFINZI (Biological) $525.00
- Truqap (Drug) $525.00
- SIR-Spheres Microspheres (Device) $347.27
- ELIQUIS (Drug) $229.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fort Worth
Dr. Saravanan Balamuthusamy, M.d, M.D
Internal Medicine — Payments: $449,579
Internal Medicine $449,579
Stevan Gonzalez, Md, MD
Internal Medicine — Payments: $366,565
Internal Medicine $366,565
Tasneem Ahmed, D.o, D.O
Internal Medicine — Payments: $229,979
Internal Medicine $229,979
Laura Armas-Kolostroubis, Md, MD
Internal Medicine — Payments: $48,384
Internal Medicine $48,384
Dr. Robert Keller, Md, MD
Internal Medicine — Payments: $46,706
Internal Medicine $46,706
Dr. Rohit Puskoor, M.d, M.D
Internal Medicine — Payments: $39,688
Internal Medicine $39,688